IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Head and Neck Squamous Cell Carcinoma
Related studies linked through entity extraction aliases.
Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab
- Status
- UNKNOWN
- Phase
- PHASE2
Neoadjuvant DaRT for Locally Advanced Oral Cavity SCC
- Status
- NOT_YET_RECRUITING
- Phase
- NA
Single Modality Trans Oral Robotic Surgery for Primary Oropharyngeal Cancer: Exploring the Impact of Surgical Margins on Local Disease Recurrence
- Status
- UNKNOWN
- Phase
- N/A
A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC
- Status
- RECRUITING
- Phase
- NA
A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN)
- Status
- RECRUITING
- Phase
- PHASE3
Virtual Reality 3D-Surgery Modeling to Enhance Head and Neck Cancer Surgery Quality
- Status
- RECRUITING
- Phase
- NA
Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery
- Status
- UNKNOWN
- Phase
- PHASE2
PD-L1 Expression on CTCs in HNSCC Patients Underwent Curative CCRT
- Status
- UNKNOWN
- Phase
- N/A
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Status
- RECRUITING
- Phase
- PHASE1
Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1
- Status
- UNKNOWN
- Phase
- PHASE2
GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients
- Status
- WITHDRAWN
- Phase
- PHASE2
TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China
- Status
- RECRUITING
- Phase
- PHASE2
Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2